WCG has launched the WCG Study Accelerator, an integrated solution designed to optimise the clinical trial process and enhance outcomes for institutions and sponsors worldwide.
The solution focuses on expediting the execution of trials by aligning site choices, ethical reviews, and subject recruitment and retention into a unified strategy.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It uses operational intelligence and real-time data to reduce risks, prevent engagement with underperforming sites, and shorten trial timelines by up to 20%. This approach allows sponsors to make informed site selections and improve enrolment efficiency.
WCG chief operations officer Mark McDonald said: “Study Accelerator not only provides a structured framework for executing trials efficiently, but also embeds flexibility and insights by streamlining site selection and participant enrolment and engagement processes.
“The solution combines advanced technology with hands-on support to ensure seamless implementation and execution, even for highly specialised or complex protocols. This truly enables smarter, faster trials.”
According to the company, operational challenges, rather than scientific uncertainty, often cause delays in the trials.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIssues such as disjointed planning, inconsistent execution of the site, and last-minute efforts to meet enrolment targets can lead to time wastage, increased expenses, and jeopardised outcomes.
The solution is specifically engineered to solve these issues by integrating core operational functions into a performance-oriented framework that enhances decision-making, minimises obstacles, and enables trial advancement.
WCG CEO Sam Srivastava said: “With the launch of WCG Study Accelerator, we are addressing the well-known bottlenecks that have plagued clinical trials for years. Our solution exemplifies our commitment to innovation and customer-centricity by providing a model that propels trial execution forward with precision, speed, and integrity.”
In March 2025, WCG launched ClinSphere Total Feasibility, a software-as-a-service (SaaS) platform aimed at refining site selection processes to aid sponsors and contract research organisations in making more decisions during clinical trial start-ups.
